SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

The effects of a second generation p38 mitogen-activated protein kinase (MAPK) inhibitor, SB 239063 [trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridim idi n-4-yl)imidazole; IC(50) = 44 nM vs. p38 alpha], were assessed in models that represent different pathological aspects of chronic obstructive pulmonary disease (COPD) [airway neutrophilia, enhanced cytokine formation and increased matrix metalloproteinase (MMP)-9 activity] and in a model of lung fibrosis. Airway neutrophil infiltration and interleukin (IL)-6 levels, assessed by bronchoalveolar lavage 48 h after lipopolysaccharide (LPS) inhalation, were inhibited dose dependently by 3-30 mg/kg of SB 239063 given orally twice a day. In addition, SB 239063 (30 mg/kg orally) attenuated IL-6 bronchoalveolar lavage fluid concentrations (>90% inhibition) and MMP-9 activity (64% inhibition) assessed 6 h after LPS exposure. In guinea pig cultured alveolar macrophages, SB 239063 inhibited LPS-induced IL-6 production (IC(50) of 362 nM). In a bleomycin-induced pulmonary fibrosis model in rats, treatment with SB 239063 (2.4 or 4.8 mg/day via osmotic pump) significantly inhibited bleomycin-induced right ventricular hypertrophy (indicative of secondary pulmonary hypertension) and increases in lung hydroxyproline synthesis (indicative of collagen synthesis and fibrosis). Therefore, SB 239063 demonstrates activity against a range of sequelae commonly associated with COPD and fibrosis, supporting the therapeutic potential of p38 MAPK inhibitors such as SB 239063 in chronic airway disease.

[1]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[2]  D E Griswold,et al.  Inhibition of p38 MAP kinase as a therapeutic strategy. , 2000, Immunopharmacology.

[3]  R R Osborn,et al.  SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  R. Flavell,et al.  Airway hyperresponsiveness and airway obstruction in transgenic mice. Morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. , 2000, American journal of respiratory cell and molecular biology.

[5]  D. Underwood,et al.  DIFFERENCES IN TIME-RELATED CARDIOPULMONARY RESPONSES TO HYPOXIA IN THREE RAT STRAINS , 2000, Clinical and experimental hypertension.

[6]  Lee,et al.  Purpose of the conference , 1990, American journal of respiratory and critical care medicine.

[7]  A. Knox,et al.  Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[8]  S. Shapiro,et al.  The macrophage in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[9]  P. Barnes,et al.  Novel approaches and targets for treatment of chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[10]  G. Ciliberto,et al.  IL‐6 knock‐out mice exhibit resistance to splanchnic artery occlusion shock , 1999, Journal of leukocyte biology.

[11]  M. Lindsay,et al.  SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. , 1999, The Journal of pharmacology and experimental therapeutics.

[12]  P. Jeffery,et al.  Differences and similarities between chronic obstructive pulmonary disease and asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[13]  S. Kassis,et al.  p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. , 1999, Pharmacology & therapeutics.

[14]  T. Horie,et al.  Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase. , 1999, American journal of respiratory and critical care medicine.

[15]  R. Hajjar,et al.  Signaling pathways mediating the response to hypertrophic stress in the heart. , 1999, Gene expression.

[16]  K. Chung,et al.  Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.

[17]  D. Welsh,et al.  Hypoxic stimulation of the stress-activated protein kinases in pulmonary artery fibroblasts. , 1998, American journal of respiratory and critical care medicine.

[18]  E. Moore,et al.  p38 mitogen-activated protein kinase inhibition attenuates intercellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells. , 1998, Surgery.

[19]  E. Moore,et al.  Interleukin-6 augments neutrophil cytotoxic potential via selective enhancement of elastase release. , 1998, The Journal of surgical research.

[20]  D. Boyd,et al.  Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. , 1998, Cancer research.

[21]  John C. Lee,et al.  Hemopoietic Growth Factors with the Exception of Interleukin-4 Activate the p38 Mitogen-activated Protein Kinase Pathway* , 1997, The Journal of Biological Chemistry.

[22]  D. Underwood,et al.  Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. , 1996, American journal of respiratory and critical care medicine.

[23]  E. Campbell,et al.  Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. , 1996, Journal of immunology.

[24]  M. Burdick,et al.  Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. , 1994, Journal of immunology.

[25]  P. Jeffery Comparative morphology of the airways in asthma and chronic obstructive pulmonary disease. , 1994, American journal of respiratory and critical care medicine.

[26]  W. MacNee,et al.  Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. , 1994, American journal of respiratory and critical care medicine.

[27]  C. M. Steel,et al.  Regulation of ICAM‐1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast‐derived factors , 1994, International journal of cancer.

[28]  J. Lee,et al.  Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock. , 1992, Circulatory shock.

[29]  C. R. Kelley Parts One and Two , 1992 .

[30]  Hunninghake Gw,et al.  Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers , 1983 .

[31]  R. Crystal,et al.  Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. , 1983, The American review of respiratory disease.